GLP-1 Drugs Reduce Alcohol-Associated Cirrhosis Risk by 32% vs DPP-4 Inhibitors | Research

The takeaway

GLP-1 RAs reduced alcohol-associated cirrhosis and hepatic decompensation risk by 32% vs DPP-4 inhibitors (HR 0.684) in T2D patients with AUD, with even stronger protection (67% reduction vs insulin) in obese patients.

67% less cirrhosis (obese)
Obese diabetic patients with AUD had 67% lower cirrhosis risk on GLP-1 drugs vs insulin — among the strongest liver protection signals reported

What the researchers found

GLP-1 RA vs DPP-4i: cirrhosis/decompensation HR 0.684 (0.615-0.762). GLP-1 vs insulin (obese): HR 0.327 (0.263-0.406). GLP-1 vs insulin (non-obese): HR 0.222 (0.133-0.373). GLP-1 vs metformin: HR 0.87 (NS).

Why it matters

Alcohol-associated cirrhosis is rising globally. A widely available drug reducing cirrhosis risk by 32-78% could save thousands of lives.

How the study worked

TriNetX retrospective study (2010-2022), T2D+AUD patients, propensity-matched comparisons of GLP-1 RA vs DPP-4i/metformin/sulfonylurea/TZD/insulin/SGLT2i for cirrhosis and decompensation outcomes.

What this study cannot tell us

Retrospective. Cannot determine if alcohol reduction contributes (GLP-1 drugs reduce drinking). AUD identification by ICD codes. Cirrhosis diagnosis timing uncertainty.

How to read the evidence

Large propensity-matched retrospective study with multiple active comparators and consistent effects.

When this study was published

Published in 2025.

The bigger picture

GLP-1 drugs may prevent liver fibrosis and cirrhosis through anti-inflammatory and anti-fibrotic mechanisms, adding liver protection to their growing benefit portfolio.

Questions still open

Is the cirrhosis protection due to reduced alcohol intake or direct liver effects?
Should GLP-1 drugs be standard for all T2D+AUD patients?
Would GLP-1 drugs help non-diabetic AUD patients prevent cirrhosis?

Common questions

Can GLP-1 drugs prevent liver cirrhosis from alcohol?

In diabetic patients with alcohol use disorder, GLP-1 drugs reduced cirrhosis risk by 32-78% depending on the comparison group. This may be through both reducing alcohol consumption and directly protecting the liver.

Should people who drink heavily take GLP-1 drugs?

For those with both diabetes and AUD, the evidence strongly supports GLP-1 drugs. Whether non-diabetic heavy drinkers would benefit needs separate study.

Read the original research

Glucagon-like peptide-1 receptor agonist reduces risk of alcohol-associated cirrhosis in type 2 diabetes and alcohol use disorder patients.

European journal of gastroenterology & hepatology

View on PubMed ↗Publisher’s paper ↗

Citation

Hwang, Soo Young; Hsieh, Pinghsin; Díaz, Luis Antonio; Goodman, Russell P; Schaefer, Esperance A; Wong, Robert J; Luther, Jay; Zhang, Wei. (2026). Glucagon-like peptide-1 receptor agonist reduces risk of alcohol-associated cirrhosis in type 2 diabetes and alcohol use disorder patients.. European journal of gastroenterology & hepatology. https://doi.org/10.1097/MEG.0000000000003162